In situ Expression of Tumor Antigens by Messenger RNA–Electroporated Dendritic Cells in Lymph Nodes of Melanoma Patients
- 1 April 2009
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (7) , 2927-2934
- https://doi.org/10.1158/0008-5472.can-08-3920
Abstract
Electroporation of dendritic cells (DC) with mRNA encoding tumor-associated antigens (TAA) for cancer immunotherapy has been proved efficient and clinically safe. It obviates prior knowledge of CTL and Th epitopes in the antigen and leads to the presentation of multiple epitopes for several HLA alleles. Here we studied the migration capacity and the antigen expression of mRNA-electroporated DC (mRNA-DC) in lymph nodes after vaccination in melanoma patients. DC were electroporated with mRNA encoding gp100 or tyrosinase, labeled with indium-111 and superparamagnetic iron oxide particles, and injected intranodally in melanoma patients 24 to 48 hours before scheduled dissection of regional lymph nodes. Immunohistochemical analysis of the lymph nodes after surgery revealed that mRNA-DC migrated from the injection site into the T-cell areas of the same and subsequent lymph nodes, where they expressed the antigen encoded by the electroporated mRNA. Furthermore, vaccine-related CD8+ T-cell responses could be detected in 7 of 11 patients vaccinated with mRNA-DC. Together these data show that mature DC electroporated with mRNA encoding TAA migrate and express antigens in the lymph nodes and induce specific immune responses. [Cancer Res 2009;69(7):2927–34]Keywords
This publication has 35 references indexed in Scilit:
- Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migrationCancer Immunology, Immunotherapy, 2008
- Development of 111In-labeled tumor-associated antigen peptides for monitoring dendritic-cell-based vaccinationNuclear Medicine and Biology, 2006
- Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapyNature Biotechnology, 2005
- Vaccination of Advanced Hepatocellular Carcinoma Patients with Tumor Lysate-Pulsed Dendritic CellsJournal of Immunotherapy, 2005
- Immunomonitoring Tumor-Specific T Cells in Delayed-Type Hypersensitivity Skin Biopsies After Dendritic Cell Vaccination Correlates With Clinical OutcomeJournal of Clinical Oncology, 2005
- Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccinesGene Therapy, 2005
- Fusion Cell Vaccination of Patients with Metastatic Breast and Renal Cancer Induces Immunological and Clinical ResponsesClinical Cancer Research, 2004
- Autologous Dendritic Cell Vaccines for Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytesGene Therapy, 2003
- Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic CellsThe Journal of Experimental Medicine, 2002